ECE2010 Poster Presentations Bone/Calcium (56 abstracts)
Imatinib mesylate disturbs bone growth and remodellation in postnatal rats
Mirja Nurmio 1 , Henna Joki 1 , Jenny Kallio 1 , Jorma Määttä 1 , Kalervo Väänänen 1 , Jorma Toppari 1 , Kirsi Jahnukainen 2, & Tiina Laitala-Leinonen 1
1University of Turku, Turku, Finland; 2Karolinska Institutet and University Hospital, Stockholm, Sweden; 3Hospital for Children and Adolescents, Helsinki, Finland.
Imatinib mesylate is a well-tolerated receptor tyrosine kinase inhibitor that has gained interest as a potential treatment for osteoporosis and other metabolic bone diseases. It is clinically approved for the treatment of chronic myelogenous leukaemia (CML), Philadelphia-positive acute lymphoblastic leukaemia and gastrointestinal stromal tumors (GIST), and targets the receptors for PDGFs, ABL-related gene, c-Abl, c-Kit and c-Fms. Altered bone and mineral metabolism has been described in patients receiving imatinib mesylate, and recent clinical data show that treating children with imatinib may result in bone loss. However, the precise effects on the bone microenvironment are unclear. We therefore exposed young rats to imatinib (150 mg/kg) on postnatal days 5–7, and studied the effects of tyrosine kinase inhibition on bone physiology on postnatal days 8 and 77.
Short-term imatinib treatment disturbed growth plate organization and eliminated all osteoclasts from the endochrondral junction. Peripheral quantitative computer tomography (pQCT) and micro-CT analysis confirmed that short-term imatinib treatment lead to a long-term resorption arrest at the growth plate and simultaneous bone loss at distal bone trabeculi. The impaired bone remodellation observed on postnatal day 8 remained significant until adulthood. The adverse effects were even more pronounced in another series of 14-day old animals that were given 100 mg/kg of imatinib on postnatal days 5–13. Therefore, clinicians prescribing tyrosine kinase inhibitors of receptors for c-Kit, c-Fms, PDGF-α or PDGF-β for children, should monitor their cancer patients also for possible adverse effects on bone growth and remodelling.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more